

Resource Summary Report

Generated by ASWG on Aug 8, 2026

Ultra-LEAF(TM) Purified anti-human CD28

RRID:AB_11148949

Type: Antibody

Proper Citation

BioLegend Cat# 302934, RRID:AB_11148949

Antibody Information

URL: http://antibodyregistry.org/AB_11148949

Proper Citation: BioLegend Cat# 302934, RRID:AB_11148949

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_11148949

Vendor: BioLegend

Catalog Number: 302934

Alternative Catalog Numbers: 302943, 302933, 302944, 302959, 302960

Record Creation Time: 20250820T040744+0000

Record Last Update: 20250820T180740+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Suzuki K, et al. (2026) Targeting the $\alpha 5 \beta 1$ Integrin Modifies the TGF β -Rich Tumor Microenvironment of Pancreatic Cancer. Cancer research, 86(15), 3801.

Tripathi A, et al. (2026) Ciclopirox reprograms effector responses and modulates Notch1 activation in activated human T cells. iScience, 29(6), 116079.

Heiduk M, et al. (2026) Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. JCI insight, 11(2).

Tripathi A, et al. (2026) Protocol for intranuclear Nrf2 detection in activated mouse, human, and Jurkat T cells by spectral flow cytometry. STAR protocols, 7(1), 104360.

Powers JS, et al. (2026) Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies. Cell reports. Medicine, 7(3), 102636.

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. Immunity, 59(5), 1201.

Galvez NMS, et al. (2026) HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. Immunity, 59(3), 768.

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4⁺ memory. iScience, 29(5), 115593.

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell reports, 45(1), 116796.

Jones RD, et al. (2026) Tunable differentiation of human CD4⁺ and CD8⁺ T cells from pluripotent stem cells. Cell stem cell, 33(1), 73.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell reports. Medicine, 7(5), 102782.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. *EBioMedicine*, 120, 105946.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. *Cancer cell*, 43(1), 103.

Li T, et al. (2025) Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. *Molecular cell*, 85(13), 2517.

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. *Cell reports. Medicine*, 6(9), 102298.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102307.

Ma K, et al. (2025) Succinate preserves CD8+ T cell fitness to augment antitumor immunity. *Immunity*.

Chimote AA, et al. (2025) Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer. *bioRxiv : the preprint server for biology*.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. *Cell*, 188(25), 7099.